Clinical Gastroenterology and Hepatology, published by Elsevier Science Inc, stands as a leading journal in the fields of gastroenterology and hepatology. With an ISSN of 1542-3565 and an E-ISSN of 1542-7714, this esteemed publication has earned its place in the top quartile (Q1) of both gastroenterology and hepatology categories as of 2023, ranking 6th out of 167 and 7th out of 82 respectively. The journal aims to disseminate innovative research, clinical studies, and case reports that advance the understanding and treatment of gastrointestinal and liver diseases. Targeted towards researchers, healthcare professionals, and students, it provides crucial insights into emerging therapies and medical advancements. Clinical Gastroenterology and Hepatology is not only a pivotal resource for contemporary gastroenterological research but also fosters collaboration and knowledge-sharing within the medical community. With a converging publication history from 2003 to the present, the journal continues to build on its solid foundation of scientific excellence and relevance.

Hepatology International is a premier academic journal dedicated to advancing the field of liver research and hepatology. Published by SPRINGER, this journal boasts a prestigious Q1 ranking in Hepatology as of 2023, underscoring its commitment to high-quality research dissemination. The journal’s scope encompasses a wide range of topics related to liver disease, including clinical, translational, and basic science studies. With its impact factor reflecting its relevance and influence in the field, Hepatology International serves as an essential resource for researchers, clinicians, and students aiming to keep abreast of the latest developments and breakthroughs. Though traditionally a subscription-based journal, it offers a vast array of insightful articles that contribute significantly to our understanding of hepatological conditions. The journal continues its trajectory of growth since its inception in 2008, anticipating a convergence of knowledge and innovation through to 2024. Located in the heart of New York City, this journal not only represents a crucial platform for global hepatology research but also fosters a collaborative community of experts dedicated to improving liver health worldwide.

INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.